SCHEMBL7068624

SCHEMBL7068624

CCCCCCNC1=NSc2cnccc2N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LATS1 O95835 2/20 0.39
LATS2 Q9NRM7 2/20 0.39
KDM6B O15054 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
IDO1 P14902 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NAAA Q02083 1/20 0.35
GBA1 P04062 1/20 0.34
KDM4E B2RXH2 1/20 0.33
HCAR3 P49019 1/20 0.33
KCNH3 Q9ULD8 2/20 0.33
MMP3 P08254 1/20 0.33
UTS2R Q9UKP6 1/20 0.32
CNR2 P34972 1/20 0.32
FAAH O00519 1/20 0.31
DNM2 P50570 2/20 0.31
ELANE P08246 2/20 0.31
ADRA2A P08913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7067430 1.00 LATS1 (0.39) LATS1LATS2KDM6BKDM4CGAA
SCHEMBL16974843 0.79 ACHE (0.38) MMP3UTS2R
SCHEMBL8582984 0.77 MMP3 (0.33) MAPTHCAR3KCNH3MMP3ADRA2A
SCHEMBL8583950 0.75 ABL1 (0.38) MMP3DNM2
SCHEMBL8720426 0.75 GAA (0.38) GAAMAPTIDO1L3MBTL1
SCHEMBL8720094 0.75 L3MBTL1 (0.38) GAAMAPTIDO1L3MBTL1
SCHEMBL8716348 0.73 MMP3 (0.33) LATS1LATS2HCAR3MMP3UTS2R
SCHEMBL8716338 0.73 MMP3 (0.33) LATS1LATS2HCAR3MMP3UTS2R
SCHEMBL6618893 0.72 LATS1 (0.40) LATS1LATS2KDM6BKDM4CNAAA
SCHEMBL16974910 0.71 MEN1 (0.38) MAPTL3MBTL1KDM4EKCNH3MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003105896-A1 COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND NOVO NORDISK A/S (DK) 2003-12-24 WO claimed
WO-2003045954-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 WO claimed
WO-2003045955-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 WO claimed
WO-2002000222-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER NOVO NORDISK A/S (DK) 2002-01-03 WO claimed
WO-2002000223-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION NOVO NORDISK A/S (DK) 2002-01-03 WO claimed
WO-2003105896-A1 COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND NOVO NORDISK A/S (DK) 2003-12-24 WO disclosed
WO-2003045954-A1 USE OF SELECTIVE POTASSIUM CHANNEL OPENERS NOVO NORDISK A/S (DK) 2003-06-05 WO disclosed
WO-2002000222-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER NOVO NORDISK A/S (DK) 2002-01-03 WO disclosed
WO-2002000223-A1 USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION NOVO NORDISK A/S (DK) 2002-01-03 WO disclosed
EP-0877748-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1998-11-18 EP disclosed
WO-1997026264-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1997-07-24 WO disclosed